Completed PHASE1 INTERVENTIONAL 4-arm NCT04157712

Multiple Ascending Dose Study of ALZ-801

A Phase I, Single Centre, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics in Plasma and Urine of Multiple Ascending Doses of ALZ-801 in Healthy Elderly Subjects

Sponsor: Alzheon Inc.

Conditions Alzheimer Disease

Interventions ALZ-801 or matching placebo

Updated 4 times since 2019 Last updated: Nov 15, 2019 Started: Sep 26, 2015 Primary completion: Jul 4, 2016 Completion: Jul 4, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Alzheimer Disease and is currently completed. Alzheon Inc. leads this study, which shows 4 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alzheon Inc.
Quotient Clinical

Data source: Alzheon Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ruddington, United Kingdom